Skip to main content
. 2020 Jan 15;5(4):411–419. doi: 10.1001/jamacardio.2019.5323

Figure 3. Comparison of Hemocompatibility-Associated Adverse Events With HeartMate 3 vs HeartMate II Devices in the Bridge to Transplant (BTT)/Bridge to Transplant Candidacy (BTC) and Destination Therapy (DT) Cohorts.

Figure 3.

Poisson regression was used to calculate the P value and relative risk (comparing HeartMate 3 [HM3] and HeartMate II [HMII] devices).